GPR44 Radiotracer for Precise Beta Cell Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for assessing beta cells in diabetes are indirect and lack precision, hindering advancements in diabetic therapies and islet transplantation.

Innovation Solution

Development of a compound or pharmaceutical composition that includes a formula with specific substituents, which can be used to detect the level of G-protein-coupled receptor 44, allowing for precise characterization of beta cells through administration and detection in subjects or tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If indirect measures such as blood glucose are used to assess beta cells, then the assessment method is simple and non-invasive, but the measurement precision and characterization accuracy are limited

Engineering Contradiction:

Improvebeta cell characterization accuracyVSAvoiddetection method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses GPR44 as an intermediary marker to indirectly detect beta cells. The compound binds to GPR44 receptors on beta cell surfaces, serving as a mediator that allows PET imaging to visualize beta cells without directly measuring beta cell function or mass. This resolves the contradiction by providing accurate beta cell characterization through an intermediary pathway rather than direct measurement.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the detection parameter from blood glucose levels to GPR44 receptor expression levels on beta cell surfaces. By targeting a specific molecular marker (GPR44) that is uniquely expressed on beta cells, the method achieves higher measurement precision while maintaining the non-invasive nature of PET imaging.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If PET imaging is used to directly detect beta cells, then the measurement precision and safety are improved, but the device complexity and technical requirements increase

Engineering Contradiction:

Improvebeta cell detection safety and precisionVSAvoidimaging technology complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The radiolabeled compound acts as an intermediary that bridges PET imaging technology and beta cell detection. The compound consists of a GPR44-binding moiety linked to a radiolabel, creating a mediator that allows the PET system to specifically visualize beta cells through their GPR44 receptors, thereby improving reliability while utilizing existing PET infrastructure.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces indirect functional assessments (blood glucose measurements) with direct molecular imaging using radiolabeled compounds. This substitution of detection mechanics enables visualizing beta cell mass and distribution in vivo with high precision, overcoming the limitations of indirect measures while leveraging the established safety profile of PET imaging.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Loss of information

If indirect measures are used for beta cell assessment, then the ease of operation is maintained, but the loss of information about beta cell function and mass occurs

Engineering Contradiction:

Improvebeta cell mass and function dataVSAvoidassessment method simplicity

Core Design Contradiction:

Loss of informationVSEase of operation

Solution Approach 1:

GPR44 serves as an information-rich intermediary marker that is specifically and highly expressed on beta cell surfaces. By targeting this intermediary, the method retrieves detailed information about beta cell mass, distribution, and potentially function without complicating the operational procedure, as PET imaging and radiotracer administration remain straightforward processes.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The radiolabeled compound enables visual detection and quantification of beta cells through radioactive signal emission, analogous to color changes in other detection methods. This allows direct visualization and measurement of beta cell mass and distribution in vivo, recovering information that was previously lost to indirect measures, while maintaining ease of operation through standard PET imaging protocols.

Inventive Principle:

Principle #32Color changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables safe and precise detection of beta cells, potentially overcoming limitations in diabetic therapies and islet transplantation by providing a direct and effective method for assessing beta cell function.

Implementation Method 1

R2 is —18F

Methodology Applied

Scientific EffectRadioactive decay: Radioactive Decay

Implementation Method 2

the compound binds to G-protein-coupled receptor 44

Methodology Applied

Scientific EffectRadiotracer binding:

Data Source

PatentUS20240002376A1Compositions and methods for g-protein-coupled receptor 44 detection

Publication Date: 2024.01.04 KANDEEL FOUAD

AI summary

Disclosed herein, inter alia, are compounds and methods for G-protein-coupled receptor 44 detection.